Single-center Randomized Study Evaluating of Oncological Benifits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With Locally Advanced Gastric Cancer in Patients With Cyt-.

St. Petersburg State Pavlov Medical University1 site in 1 country304 target enrollmentFebruary 10, 2020

ConditionsPeritoneal Carcinomatosis Gastric Cancer

InterventionsStaging laparoscopy 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel Radical surgery PIPAC Adjuvant chemotherapy

Drugs5-Fluorouracil Leucovorin Oxaliplatin Docetaxel Adjuvant chemotherapy

Overview

Phase: Not Applicable
Intervention: Staging laparoscopy
Conditions: Peritoneal Carcinomatosis
Sponsor: St. Petersburg State Pavlov Medical University
Enrollment: 304
Locations: 1
Primary Endpoint: Comparison of Overall survival (OS) in both arms
Status: Recruiting
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

Stomach cancer is recognized as the third leading cause of death of cancer patients worldwide. Despite the radical treatment carried out, the progression of gastric cancer occurs in 30-40% of patients. The most common type of tumor progression of this localization is peritoneal carcinomatosis. When peritoneal carcinomatosis occurs, the median survival of patients does not exceed 3 months, the overall survival is no more than 6 months. Unfortunately, when peritoneal carcinomatosis occurs, palliative chemotherapy remains the only treatment option. The modern strategy for the prevention and treatment of peritoneal carcinomatosis is based on the concept of regional chemotherapy. The main methods of regional chemotherapy are hyperthermic intraperitoneal chemotherapy (HIPEC) and Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC). PIPAC is a new technology for delivering chemotherapy drugs to tumor nodes on the surface of the peritoneum and allows the cytostatic to be evenly distributed over the abdominal cavity, increasing the depth of its penetration into tumor nodes due to the properties of aerosol and gradients of intra-abdominal and interstitial pressure. The method has a number of advantages over the HIPEC method: a large penetration depth of drugs, low trauma, the possibility of repeated use. We offer PIPAC for patients with locally advanced gastric cancer and a high risk of developing peritoneal carcinomatosis in an adjuvant mode in addition to standard treatment to prevent the development of carcinomatosis.

Detailed Description

The study is interventional: patients over 18 years of age with an established diagnosis of stomach cancer (c)T3-4N0-3M0 CYT- will be randomized into 2 groups using the envelope method. The control group will receive only neoadjuvant chemotherapy + gastrectomy/ distal subtotal resection with D2 lymph node dissection, the active comparison group - neoadjuvant chemotherapy + gastrectomy with D2 lymph node dissection + PIPAC (Cisplatin (7.5 mg / m²) + Doxirubicin 1.5 mg / m2)). Will be assessed: overall survival, median survival, disease-free survival, quality of life of patients.

Registry

clinicaltrials.gov

Start Date

February 10, 2020

End Date

January 10, 2029

Last Updated

5 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

St. Petersburg State Pavlov Medical University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Histologically confirmed, medically operable, resectable stomach adenocarcinoma (cT3-4, any N category, M0).
•No preceding cytotoxic or targeted therapy.
•No prior partial or complete tumor resection.
•Female and male patient ≥ 18 and ≤ 75 years. Female patient with childbearing potential needs to have a negative pregnancy test within 7 days prior to study start. Males and females of reproductive potential must agree to practice highly effective contraceptive measures\* during the study. Male patients must also agree to refrain from father a child during treatment and additionally to use a condom during treatment period. Their female partner of childbearing potential must also agree to use an adequate contraceptive measure.
•\*highly effective (i.e. failure rate of \<1% per year when used consistently and correctly) methods: intravaginal and transdermal combined (estrogen and progestogen containing) hormonal contraception; injectable and implantable progestogen-only hormonal contraception; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomised partner; sexual abstinence (complete abstinence is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments).
•ECOG = 0-
•Exclusion of distant metastases by CT or MRI of abdomen, pelvis, and thorax, bone scan or MRI (if bone metastases are suspected due to clinical signs). Exclusion of the infiltration of any adjacent organs or structures by CT or MRI.
•Laparoscopic exclusion of peritoneal carcinomatosis at initial staging, before start of FLOT chemotherapy
•Adequate hematological, hepatic and renal function parameters:
•Leukocytes ≥ 3000/mm³, platelets ≥ 100,000/mm³, neutrophil count (ANC) ≥1000/µL Serum creatinine ≤ 1.5 x upper limit of normal Bilirubin ≤ 1.5 x upper limit of normal, AST and ALT ≤ 3.0 x upper limit of normal, alkaline phosphatase ≤ 6 x upper limit of normal For patients not receiving therapeutic anticoagulation: INR or aPTT ≤ 1.5 x ULN; for patients receiving therapeutic anticoagulation: stable anticoagulant regimen.

Exclusion Criteria

•Patient without neoadjuvant therapy or those who received a neoadjuvant therapy other than FLOT.
•Known hypersensitivity against 5-FU, leucovorin, oxaliplatin, or docetaxel.
•Other known contraindications against, 5-FU, leucovorin, oxaliplatin, or docetaxel.
•Clinically significant active coronary heart disease, cardiomyopathy or congestive heart failure, NYHA III-IV.
•Clinically significant valvular defect.
•Criteria of primary unresectability, e.g.:
•Radiologically documented evidence of major blood vessel invasion or invasion of adjacent organs (T4b).
•Patients with involved retroperitoneal (e.g. para-aortal, paracaval or interaortocaval lymph nodes) or mesenterial lymph nodes (distant metastases!).
•Other severe internal disease or acute infection.
•Peripheral polyneuropathy ≥ NCI Grade II.

Arms & Interventions

PIPAC group

Outcomes

Primary Outcomes

Comparison of Overall survival (OS) in both arms

Time Frame: from randomization up to 5 years

Overall survival (OS) where OS is defined as the time from randomization to death from any cause.

Secondary Outcomes

PFS/DFS rates at 2, 3 & 5 years(2, 3 & 5 years after randomization)
Comparison of Overall survival rates at 3 and 5 years in both arms(3 and 5 years after randomization)
Comparison of progression-/disease-free survival (PFS/DFS) between arms(from randomization up to 5 years)
Comparison of peritoneal relapse rate in both arms(from randomization up to 5 years)
Rate of surgical serious adverse events (SAEs)(After randomization of the patient until 30 days after last study-specific treatment)
Patient reported outcomes: Quality of life EORTC QLQ C30 questionnaire(From date of screening until the date of first documented progression or last visit before date of death from any cause, whichever came first, assessed 8 weeks +/- 7 days until EOT, afterwards every 3 months up to 2 years after last patient in)
Rate of post-operative morbidity/mortality at day 30 after surgery acc. to Clavien-Dindo classification(at day 30 after surgery)
Patient reported outcomes: VAS pain assessment form(From date of screening until the date of first documented progression or last visit before date of death from any cause, whichever came first, assessed 8 weeks +/- 7 days until EOT, afterwards every 3 months up to 2 years after last patient in)